Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition

Acute myeloid leukemia (AML) is a disease with great morphological and genetic heterogeneity, which complicates its prognosis and treatment. The hypomethylating agents azacitidine (Vidaza(®), AZA) and decitabine (Dacogen(®), DAC) have been approved for the treatment of AML patients, but their mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Raneros, Aroa Baragaño, Puras, Alfredo Minguela, Rodriguez, Ramon M., Colado, Enrique, Bernal, Teresa, Anguita, Eduardo, Mogorron, Adela Vasco, Gil, Alberto Chaparro, Vidal-Castiñeira, Jose Ramon, Márquez-Kisinousky, Leonardo, Bulnes, Paula Díaz, Marin, Amelia Martinez, Garay, García Maria Carmen, Suarez-Alvarez, Beatriz, Lopez-Larrea, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458262/
https://www.ncbi.nlm.nih.gov/pubmed/28404876
http://dx.doi.org/10.18632/oncotarget.16657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458262/
https://www.ncbi.nlm.nih.gov/pubmed/28404876
http://dx.doi.org/10.18632/oncotarget.16657

Ejemplares similares